Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

This was the stock's second consecutive day of losses.

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead Sciences ( NASDAQ: GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The stock’s 50-day moving average is $92.71 and its two-hundred day moving average is $86.32.

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $100.51. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after market close. The Zacks Consensus Estimate for sales and earnings is ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...